---
title: "Abpro Holdings chairman Miles Suk resigns, stays on board"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297632832.md"
description: "Miles Suk resigned as chairman of the board at Abpro Holdings Inc. on August 25, 2026, but will remain a board member. The company plans to appoint a successor chair at its next regularly scheduled meeting."
datetime: "2026-09-01T10:03:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297632832.md)
  - [en](https://longbridge.com/en/news/297632832.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297632832.md)
generator: "portal-rs"
---

# Abpro Holdings chairman Miles Suk resigns, stays on board

-   Miles Suk resigned as board chair on Aug. 25, 2026. \* Board to name a successor chair at its next regularly scheduled meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abpro Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-095822), on September 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ABPO.US](https://longbridge.com/en/quote/ABPO.US.md)
- [ABP.US](https://longbridge.com/en/quote/ABP.US.md)
- [ABPWW.US](https://longbridge.com/en/quote/ABPWW.US.md)

## Related News & Research

- [Sranan Gold changes auditor, appoints Crowe Mackay to replace DMCL](https://longbridge.com/en/news/298641449.md)
- [Singapore Index Fund amends trust deed to add electronic transfers, phase out cheques from Oct. 1, 2026](https://longbridge.com/en/news/298710637.md)
- [Damartex reports FY2025-26 annual results release available](https://longbridge.com/en/news/298344100.md)
- [BioLineRx outlines Phase 1/2a GLIX1 trial in recurrent high-grade glioma at EANO 2026](https://longbridge.com/en/news/298582374.md)
- [Vivos Therapeutics amends 8-K to correct report date to Sept. 2, 2026](https://longbridge.com/en/news/298368513.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**